Novo Nordisk A/S

Extensive work in type 2 diabetes and type 1 diabetes, with attention to blood glucose control, treatment intensification, and combinations involving basal insulin, GLP-1 receptor agonists, and SGLT2 inhibitors. Research also includes paediatric type 2 diabetes and diabetes-related complications.

• HbA1c reduction
• Insulin icodec
• Oral semaglutide
• Diabetic retinopathy

Clinical interest extends to metabolic control across age groups, including adolescents and children, with studies touching on diabetes management alongside excess body weight.